Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US3755581036
Ticker GILD
Company GILEAD SCIENCES
Currency $
Price
Aware Investor Index (AII) 69.6675
Recommendation STRONG BUY
P/E 12.18
ROE 31.49 %
Capitalization 82,587,120,000 $
Dividend Yield 3.61 %
P/S 3.73
AII Position 49
P/E Position 122
ROE Position 91
Capitalization Position 105
Dividend Yield Position 197
Sales 22,127,000,000 $
10-Year Average Earnings 6,780,002,300 $
Shares Outstanding 1,308,000,000
Equity 21,534,000,000 $
Dividend per Share 2.28 $
Industry Biotechnology
Country United States
GILEAD SCIENCES Investor Relations Web Site http://investors.gilead.com







Sales:

YEAR MONTH AMOUNT
2018 12 22,127,000,000.00 $
2017 12 26,107,000,000.00 $
2016 12 30,390,000,000.00 $
2015 12 32,639,000,000.00 $
2014 12 24,890,000,000.00 $
2013 12 11,201,680,000.00 $
2012 12 9,702,000,000.00 $
2011 12 8,385,000,000.00 $
2010 12 7,949,000,000.00 $
2009 12 7,011,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 12 5,455,000,000.00 $
2017 12 4,628,000,000.00 $
2016 12 13,501,000,000.00 $
2015 12 18,108,000,000.00 $
2014 12 12,101,000,000.00 $
2013 12 3,074,808,000.00 $
2012 12 2,591,566,000.00 $
2011 12 2,803,637,000.00 $
2010 12 2,901,257,000.00 $
2009 12 2,635,755,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 12 21,534,000,000.00 $
2017 12 20,501,000,000.00 $
2016 12 19,363,000,000.00 $
2015 12 19,113,000,000.00 $
2014 12 15,819,000,000.00 $
2013 12 11,744,501,000.00 $
2012 12 9,550,869,000.00 $
2011 12 6,867,349,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 1,308,000,000
2017 12 1,319,000,000
2016 12 1,358,000,000
2015 12 1,521,000,000
2014 12 1,647,000,000
2013 12 1,694,747,000
2012 12 1,582,549,000
2011 12 1,580,236,000

 












Bloomberg News for GILEAD SCIENCES:



Google News for GILEAD SCIENCES:

NyseNewsGuru (press release) - 6 hours ago
Tech Stock To Watch:: Gilead Sciences, Inc., (NASDAQ: GILD)
Each buying and selling session display one-of-a-kind actions and patterns about Gilead Sciences, Inc. GILD), Drug Manufacturers – Major ...
NEWS SCANNER (press release)
Goodbye To Gilead As ViiV, Merck Besiege Its HIV Citadel
At its peak in 2014-5, Gilead Sciences (GILD) had almost everything going for it. Its HCV drugs had the sales momentum and headlines.
Money Making News (press release)
If Analyst Forecast Holds: – Gilead Sciences, Inc., (NASDAQ: GILD)
On Monday, August 19, 2019, the stock (Gilead Sciences, Inc.) created a change of 1.54 percent and closed its last session of business at ...
Glenrock Gazette
Is Gilead Sciences (GILD) a Great Stock for Value Investors?
Let's put Gilead Sciences, Inc. GILD stock into this equation and find out if it is a good choice for value-oriented investors right now, or if ...
Seeking Alpha - 2 days ago
What Kind Of Investor Owns Most Of Gilead Sciences, Inc. (NASDAQ ...
A look at the shareholders of Gilead Sciences, Inc. (NASDAQ:GILD) can tell us which group is most powerful. Institutions often own shares in ...
News Planets (press release) - 5 hours ago
Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
Gilead Sciences GILD and partner Galapagos GLPG announced that the European Medicines Agency (“EMA”) has accepted their marketing ...
Yahoo Finance - 13 Aug 2019
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron ...
Chicago, IL – August 14, 2019 – Today, Zacks Equity Research discusses Biomedical and Genetics, including Gilead Sciences GILD, ...
Yahoo Finance - 12 Aug 2019
Gilead Sciences: A Very Core Holding
Gilead Sciences (GILD) has been making some moves which create some enthusiasm, although that still has to be reflected in a higher share ...
NewsSmooth (press release)
Valuation Now: – Gilead Sciences, Inc., (NASDAQ: GILD)
On Friday, August 16, 2019, the stock (Gilead Sciences, Inc.) created a change of 0.43 percent and closed its last session of business at $63.14 ...
The InvestChronicle
Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $1.82 per share, beating the Zacks Consensus Estimate of $1.74 per share.


Back